Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KIT Y823D |
| Gene Variant Detail | |
| Relevant Treatment Approaches | KIT Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KIT Y823D | Advanced Solid Tumor | sensitive | KIT Inhibitor | Motesanib Diphosphate | Preclinical - Cell culture | Actionable | In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291). | 20633291 |
| KIT Y823D | Advanced Solid Tumor | sensitive | Nintedanib | Preclinical - Cell culture | Actionable | In a preclinical study, Ofev (nintedanib) inhibited Kit autophosphorylation and proliferation of transformed cells expressing KIT Y823D in culture (PMID: 35194937). | 35194937 | |
| KIT Y823D | melanoma | predicted - sensitive | KIT Inhibitor | Ripretinib | Case Reports/Case Series | Actionable | In a Phase I trial, Qinlock (ripretinib) treatment resulted in a complete response in a patient with metastatic melanoma harboring KIT Y823D (PMID: 35753087; NCT02571036). | 35753087 |
| KIT Y823D | Advanced Solid Tumor | predicted - sensitive | KIT Inhibitor | IDRX-42 | Preclinical - Biochemical | Actionable | In a preclinical study, IDRX-42 inhibited kinase activity of KIT Y823D in an vitro assay (PMID: 40018846). | 40018846 |